BIOGEN INC.
Biological Products, (No Diagnostic Substances) · 225 BINNEY STREET, CAMBRIDGE, MA 02142
官方登記資料
0位追蹤者
1978成立於
關於 BIOGEN INC.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis ; nusinersen (Spinraza) for the treatment of spinal muscular atrophy ; omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia ; tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
Source: Wikipedia
產業Biological Products, (No Diagnostic Substances)
總部225 BINNEY STREET, CAMBRIDGE, MA 02142
成立時間1978
法律形式C Corporation
狀態營運中
專利34 項專利
THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE SCLEROSISWO2024015331A1 · 2024
PROCESS FOR PREPARING SPIRO DERIVATIVES.MX2020003821A · 2023
關鍵數據
法律資訊
| 法定名稱 | BIOGEN INC. |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 875045在 SEC EDGAR 上查看 ↗ |
| EIN | 33-0112644 |
| 產業代碼(SIC) | 2836 |
| 登記地址 | 225 BINNEY STREET, CAMBRIDGE, MA 02142 |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年10月15日